The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Background
Orbital rhabdomyosarcoma (ORMS) commonly presents as low‐risk disease (stage 1, group I–III, embryonal RMS) with excellent outcome. Long‐term follow‐up of patients with low‐risk ORMS and outcomes of less common subgroups of ORMS treated on recent Children's Oncology Group (COG) trials have not been reported.
Methods
Patients with ORMS enrolled on COG trials from 1997 to 2013 were identified...
Background
The objective of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I‐III), FOXO1 fusion‐positive rhabdomyosarcoma (RMS).
Methods
Patients with confirmed FOXO1 fusion‐positive RMS who were enrolled on 3 completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.